Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5973630 | 0.96 | TSHR (0.46) | TSHRMAPK1SNCACHRNA7TACR1 | |
| Bromide SCHEMBL17385989 | 0.90 | TACR1 (0.51) | TSHRMAPK1SNCACHRNA7TACR1 | |
| Bromide SCHEMBL21582175 | 0.89 | MAOB (0.56) | TSHRMAPK1MAOBABCB1 | |
| Bromide SCHEMBL29409809 | 0.89 | MAOB (0.56) | TSHRMAPK1MAOBABCB1 | |
| Bromide SCHEMBL3110986 | 0.86 | TAAR1 (0.56) | TAAR1MAOBABCB1 | |
| SCHEMBL31208272 | 0.84 | TAAR1 (0.57) | TAAR1MAOBABCB1 | |
| Bromide SCHEMBL1604414 | 0.84 | SNCA (0.56) | SNCALTA4HCA4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5248234 | 0.83 | TAAR1 (0.56) | TAAR1MAOBABCB1 | |
| Bromide SCHEMBL11094493 | 0.80 | CHRNA7 (0.52) | TSHRMAPK1CHRNA7TACR1ABCB1 | |
| Iodide SCHEMBL3971492 | 0.80 | LTA4H (0.55) | SNCALTA4HCA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | claimed |
| WO-2024105686-A1 | A PROCESS FOR THE SYNTHESIS OF STILBENE AND INTERMEDIATES THEREOF | FERTIS INDIA PVT LTD (IN) | 2024-05-23 | — | — | WO | disclosed |
| EP-3094318-B1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3094318-A2 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | Kannalife, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2016164703-A1 | FGFR4 INHIBITORS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2016-10-13 | — | — | WO | disclosed |
| WO-2015106108-A2 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2004033438-A1 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | THERACOS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | SEED, BRIAN | 2003-09-25 | — | — | US | disclosed |
| US-4405626-A | TRANQUILIZERS, HYPOTENSIVE AGENTS; DIURETICS; VISION DEFECTS | PFIZER INC. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4400385-A | TRANQUILIZERS, HYPOTENSIVE AGENTS; DIURETICS; VISION DEFECTS | PFIZER INC. (US) | 1983-08-23 | — | — | US | disclosed |
| US-4380542-A | ANALGESICS, TRANQUILIZERS | PFIZER (US) | 1983-04-19 | — | — | US | disclosed |
| US-4340737-A | CNS AGENTS, HYPOTENSIVES, DIURETICS AND AGENTS FOR TREATMENT OF GLAUCOMA | PFIZER INC. (US) | 1982-07-20 | — | — | US | disclosed |
| US-4260764-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4243674-A | HYPOTENSIVE AGENTS; ANALGESICS; ANTISECRETORY AGENTS; ANTIBODY INHIBITORS, AND TRANQUILIZERS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4143139-A | ANALGESICS, HYPOTENSIVES, IMMUNOSUPPRESSANTS, TRANQUILIZERS, ANTISECRETORY, ANTI-ANXIETY | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | TXNRD2, KEAP1, GOT2 | TSHR 3175/4885MAPK1 1444/4885SNCA 392/4885 |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | EPHX1, DBH, EPHX2 | TSHR 3038/4885MAPK1 3104/4885SNCA 1332/4885 |
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | TSHR 1077/4885MAPK1 1514/4885SNCA 4693/4885 |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | TXNRD2, KEAP1, GOT2 | TSHR 3175/4885MAPK1 1444/4885SNCA 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.